A venture capital firm founded with headquarters in Taipei City, Taiwan, with additional partners based in Silicon Valley, Korea, Singapore, and Japan, formed a fund with local and international investors. The firm has the capacity to invest in companies they identify as a strong fit, with initial investments typically in the $1-6 M range. The firm is looking for companies globally but would prefer companies that have Taiwan angle.

The firm is an opportunistic investor that currently considering Therapeutics, Medical Devices, Diagnostics, Biotechnology R&D, and Healthcare IT companies. The firm is open to many sectors in therapeutics but prefers companies that are into phase I of clinical trials or later. The firm is open to medical devices with all FDA regulatory pathways, including 510k, PMA, and software-enabled device. The firm invest in any phases in medical devices and diagnostics with a preference for those with in human data. The firm looks into any indications except orphan disease.

The firm currently will invest in privately held companies only. The firm has no specific requirements for management team. The firm can participate as either lead or co-investor and generally requests a board seat or board observer rights in its portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An impact venture capital firmis dedicated to funding private, early-stage whose innovation(s) significantly help or cure patients suffering from psychiatric and/or neurological diseases. The firm will invest in Seed and Series A rounds, typically allocating $200k – 8 million USD for each deal. The firm looks for deals globally and plans to make several investments in the upcoming year immediately following the first close of the fund. The firm is willing to lead rounds or co-invest as long as the investment falls within their investment criteria.

The firm is interested in devices, digital health, therapeutics, and diagnostics companies that focus on improving the treatment or curing diseases of the central nervous system. The firm prefers technologies and therapeutics that are disease modifying and/or gain significant traction in disease symptom reduction. Technologies that improve quality of life or treatment delivery in neurological and psychiatric patient populations will also be considered.

The firm sometimes prefers to take a board seat in companies in which they invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in California is interested in making equity investments into early stage companies with investments ranging from $1M to $15 million per company, depending on the company’s needs and stage of development. The firm is currently seeking investment opportunities throughout the United States.

The firm is looking for companies operating in the HIT/ Digital Health space as well as diagnostics and devices with a software component. The firm is entirely opportunistic in terms of indication and will consider companies at all stages of development. Specific areas of interest include life science tools, mental health, digital therapeutics, synthetic biology and 3D printing.

The firm is looking for privately held companies with strong management teams. The firm is able to provide entrepreneurs with a 200-person advisory network and bring deep operational expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture arm of a leading electronic solutions provider looks at life sciences as one of their main focus areas. The firm focuses on strategic investments in which the corporate could bring significant value, and those that supplement the corporate’s business areas. The firm invests up to $10M over the lifetime of the company, usually between Series A to C rounds but looks even earlier for life science-related opportunities. The firm usually invests around $5M initially and reserves capital for follow-on investment. The corporate has a global footprint, with manufacturing plants throughout USA, China, and Thailand. The firm is open to global opportunities including those in rapidly growing markets like China and India. The firm is expecting to close 3 new investments in Q1 2019.

Within the early-stage life sciences ecosystem, the firm is most interested in novel drug delivery systems with target indications including oncology, cardiovascular, diabetes, and COPD. The firm also has a strong interest in technologies with a connected health component. The firm is open to all early-stage opportunities that are relevant to the firm’s focus areas, but those who do not yet have a working prototype would be considered too early for the firm. The firm is open to all classes of devices including 510k and PMA.

The firm can act as either the lead or co-investor. The firm would prefer to see companies that already have some sort of commercial engagement established. The firm aims to bring strategic value into their portfolio companies, such as working on product design and development. If the company already has such manufacturing partnership established, it is unlikely for the firm to invest in the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global investment firm founded in 2005 has about $300 AUM and invests in a wide variety of sectors, with healthcare being one of the major areas of interest. The firm can invest anywhere from $0.25 – 25M, depending on the company’s stage of development. Currently, the firm is primarily investing in USA-based opportunities.

The firm is opportunistic in terms of technology and indication and will consider all types of technologies with high growth potential, in therapeutics, medical devices, diagnostics, and digital health sectors. The firm is the largest stakeholder in a late-clinical-stage therapeutics company, but the firm is certainly open to pre-clinical therapeutics companies as well.

The firm no specific management team requirements. The firm often leads investment rounds, but is also open to co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in Hangzhou, China  makes early-growth stage investments, preferably in series A and B, but will consider series C. The firm typically invests USD 1-30 million per company. The firm prefers to invest in companies based in China, but is open to outstanding Chinese-led companies based in the US and Canada. The firm is actively seeking new investment opportunities.

In the life sciences, the firm currently considers therapeutics and diagnostics in bone/joint diseases, renal diseases, autoimmune disease, cancer, and fibrosis. The firm is especially interested in immunotherapy, gene editing, and stem cell therapy that have preclinical data. Clinical data is desired, but not required.

The firm typically seeks Chinese-led teams with strong technical expertise and industry experience. The firm may request a board seat on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment firm with offices in the West and East Coasts invests in startups in highly regulated industries, including healthcare. The firm is interested in making investments at the seed and early venture stages; seed investments are typically $1-3 million. The firm invests globally.

The firm invests in digital health, and the firm is also interested in investing in early stage therapeutics. In the digital health space, the firm is primarily focused on technologies used by consumers/patients, and prefers to invest in companies that have revenues of at least $1 million or several customers and demonstrated product/market fit. In therapeutics, the firm is interested in preclinical technologies; the firm is open to investing in any therapeutic modality including cell and gene therapies. The firm is interested in oncology, immunology and diabetes, and will consider investing in other indication areas as well; however, antibiotics are not of interest. The firm may also consider investing in novel molecular diagnostics, provided there is a strong scientific component to the technology.

The firm is focused on investing in early stage companies, and typically invests in startups with under 15 staff. The firm focuses on finding the right team and the right science, and is interested in investing in early stage therapeutics in order to fund those companies through proof of concept studies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.